GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Equity-to-Asset

Novo Nordisk A/S (Novo Nordisk A/S) Equity-to-Asset

: 0.34 (As of Dec. 2023)
View and export this data going back to 1981. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Novo Nordisk A/S's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $15,591 Mil. Novo Nordisk A/S's Total Assets for the quarter that ended in Dec. 2023 was $46,012 Mil. Therefore, Novo Nordisk A/S's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.34.

The historical rank and industry rank for Novo Nordisk A/S's Equity-to-Asset or its related term are showing as below:

NVO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34   Med: 0.46   Max: 0.52
Current: 0.34

During the past 13 years, the highest Equity to Asset Ratio of Novo Nordisk A/S was 0.52. The lowest was 0.34. And the median was 0.46.

NVO's Equity-to-Asset is ranked worse than
74.33% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs NVO: 0.34

Novo Nordisk A/S Equity-to-Asset Historical Data

The historical data trend for Novo Nordisk A/S's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.44 0.36 0.35 0.34

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.32 0.32 0.31 0.34

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Equity-to-Asset falls into.



Novo Nordisk A/S Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Novo Nordisk A/S's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=15590.946/46012.466
=0.34

Novo Nordisk A/S's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=15590.946/46012.466
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk A/S  (NYSE:NVO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Novo Nordisk A/S Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.